Small-quantity lipid-based nutrient supplements containing different amounts of zinc along with diarrhea and malaria treatment increase iron and vitamin A status and reduce anemia prevalence, but do not affect zinc status in young Burkinabe children:

**Permalink**
https://escholarship.org/uc/item/50j5j8vs

**Journal**
BMC pediatrics, 17(1)

**ISSN**
1471-2431

**Authors**
Abbeddou, Souheila
Yakes Jimenez, Elizabeth
Somé, Jérome W
et al.

**Publication Date**
2017-02-02

**DOI**
10.1186/s12887-016-0765-9

Peer reviewed
Small-quantity lipid-based nutrient supplements containing different amounts of zinc along with diarrhea and malaria treatment increase iron and vitamin A status and reduce anemia prevalence, but do not affect zinc status in young Burkinabe children: a cluster-randomized trial

Souheila Abbeddou1, Elizabeth Yakes Jimenez2,3, Jérome W. Somé1,4, Jean Bosco Ouédraogo4, Kenneth H. Brown.1,5 and Sonja Y. Hess1*

Abstract

Background: We assessed the effects of providing a package of interventions including small-quantity lipid-based nutrient supplements (SQ-LNS) containing 0, 5 or 10 mg zinc and illness treatment to Burkinabe children from 9 to 18 months of age, on biomarkers of zinc, iron and vitamin A status at 18 months and compared with a non-intervention cohort (NIC).

Methods: Using a two-stage cluster randomized trial design, communities were randomly assigned to the intervention cohort (IC) or NIC, and extended family compounds within the IC were randomly assigned to different treatment groups. IC children (n = 2435) were provided with 20 g SQ-LNS/d containing 0, 5 or 10 mg zinc, 6 mg of iron and 400 μg of vitamin A along with malaria and diarrhea treatment. NIC children (n = 785) did not receive the intervention package. At 9 and 18 months, hemoglobin (Hb), zinc, iron and vitamin A status were assessed in a sub-group (n = 404). Plasma concentrations of zinc (pZC), ferritin (pF), soluble transferrin receptor (sTfR) and retinol-binding protein (RBP) were adjusted for inflammation.

(Continued on next page)
Background

Zinc, iron and vitamin A are essential for optimal physical growth, cognitive development and immune function of young children [1–5]. Deficiencies of these micronutrients are prevalent in sub-Saharan Africa, where approximately one fourth of the population are at risk of zinc deficiency [6], ~20% of pre-school children suffer from iron deficiency anaemia [7], and >40% of children have subclinical vitamin A deficiency, based on serum retinol concentration <0.70 μmol/L [8]. These micronutrient deficiencies often co-exist in low-income populations, and combined supplementation with zinc, iron and vitamin A is gaining traction as a strategy to decrease childhood morbidity and mortality [3, 5, 9, 10].

There are multiple potential interactions among micronutrients when they are co-supplemented. For example, some studies found that adding zinc to iron supplements reduced their impact on iron status, although a meta-analysis of available studies concluded that there was no significant effect of concomitant zinc supplementation on the response of iron status indicators and hemoglobin (Hb) to iron supplementation [10, 11]. Zinc may also affect vitamin A metabolism through its involvement in protein synthesis and cellular enzyme functions [12], but there are only a limited number of studies that have evaluated the effect of combined zinc and vitamin A supplementation on vitamin A status, and the results are inconclusive [12–14].

Home fortification of children’s foods using small-quantity lipid-based nutrient supplements (SQ-LNS) providing ~110–120 kcal/day (20 g dose) or medium-quantity lipid-based nutrient supplements (MQ-LNS) providing ~250–500 kcal/day (45–90 g dose) is a promising strategy to support normal linear growth and development in young children [15]. Despite reports of beneficial effects of SQ- and MQ-LNS on children’s growth [16–18], there is little research on their effects on micronutrient status, and the available studies have assessed only a few micronutrients. Plasma zinc concentration (pZC) did not differ between Malawian children who received 4.5–7.0 mg zinc via either MQ-LNS (40–60 g) or isocaloric fortified porridge from 6 to 18 months of age [18]. Daily supplementation of 6–12 months old Ghanaian children with SQ-LNS reduced iron deficiency anemia by 32%, but did not affect zinc status [19]. A recent study from Honduras found that supplementing children with MQ-LNS (46 to 70 g; containing 9 mg zinc, 9 mg iron, 400 μg vitamin A and 0.9 μg vitamin B12 per 46 g) from age 6 to 18 months had no effect on Hb, iron or zinc status, but significantly reduced vitamin A and vitamin B12 deficiencies [20].

The objectives of the present study were to assess 1) the effects of supplementing Burkinabe children from 9 to 18 months of age with different amounts of zinc (0, 5 or 10 mg zinc) in SQ-LNS containing 6 mg iron and 400 μg vitamin A along with the treatment of diarrhea and malaria on biomarkers of zinc, iron and vitamin A status at 18 months; and 2) the combined effect of SQ-LNS and diarrhea and malaria treatments on these indicators compared with a non-intervention cohort (NIC).

Methods

Study design

This study was a cluster randomized, partially double-masked, placebo-controlled trial (the International Lipid-based Nutrient Supplement-Zinc Trial, iLiNS-ZINC), which took place in the Dandé Health District in southwestern Burkina Faso from April 2010 to July 2012. Ethical approval was provided by the Institutional Review Boards of the Centre Muraz in Bobo-Dioulasso (Burkina Faso) and the...
University of California, Davis (USA). Caregivers provided separate written, informed consents for participation in the study and for collection of biological specimens from the child. The study was registered as a clinical trial with the U.S. National Institute of Health (https://www.clinicaltrials.gov/ct2/results?term=NCT00944281).

This trial included two levels of randomization: 1) the community and 2) the concession (extended family compound). Thirty-four communities accessible during the rainy season were stratified by health clinic catchment area and randomly allocated to intervention cohort (IC, 25 communities) or non-intervention cohort (NIC, 9 communities), in such a way to ensure balanced cohorts with respect to population size, distance from a paved road, and distance from the city of Bobo-Dioulasso. A total of 3220 children 9–10 month of age (~95% of those screened) were enrolled in the study after meeting all the enrollment criteria (Fig. 1). Of these, 2435 children were included in the IC and 785 in the NIC. Children were considered eligible if they were 8.8 to 9.9 months of age, were permanent residents of the study area, and their caregivers planned to be available during the study period and accepted weekly home visits. Children were not enrolled in the study when their Hb was <50 g/L, weight-for-length was <70th percentile of the National Center for Health Statistics/World Health Organization (NCHS/WHO) growth reference [21], or they had any illness warranting hospital referral or potentially interfering with growth, as reported previously in greater detail [22, 23] (Fig. 1).

Randomization and blinding
Within the intervention cohort, individual concessions were randomly assigned to one of eight color codes using a block randomization list prepared by a statistician from the University of California Davis. Two colors represented each treatment group, and all participants, field staff, study statistician and investigators were blinded to the intervention groups during the trial. Cluster randomization at the level of the concession was chosen to reduce the risk of cross-contamination within the family compound through food sharing.

Intervention
Children in the IC were assigned to receive one of the following daily supplements from 9 to 18 months of age: 1) SQ-LNS without added zinc, and placebo tablet (LNS-Zn0); 2) SQ-LNS with 5 mg added zinc, and placebo tablet (LNS-Zn5); 3) SQ-LNS with 10 mg added zinc, and placebo tablet (LNS-Zn10); or 4) SQ-LNS without added zinc, and 5 mg zinc tablet (LNS-TabZn5). Supplementation of children in IC started the day after the baseline screening. Children in the NIC (N = 785) did not receive SQ-LNS or tablets from 9 to 18 months of age, but received SQ-LNS with 10 mg zinc for 9 months beginning at 18 mo of age after the final blood sample was collected. Caregivers in the IC communities were instructed to administer 20 g SQ-LNS per day in two separate servings, preferably mixed in a small portion of the child’s meal, and to give the dispersible tablet once daily at least 30 min away from meals. At enrollment and throughout the study, the caregivers were advised to continue breastfeeding and feed diverse foods to the child, and IC caregivers were reminded that SQ-LNS should not replace other components of the diet. Adherence was assessed by obtaining reported information on SQ-LNS and tablet consumption, collecting any remaining SQ-

---

**Fig. 1** Flow diagram of the biochemistry indicators for iLiNS-Zinc. 1In all groups, invited if free of confirmed fever or diarrhea during the enrollment day. 2In all groups, no sample at 18 mo either because child failed to provide biological samples or because of dropout.
LNS and tablets and empty packages, and by direct observation in a subgroup of children, as reported in more detail elsewhere [24].

At baseline, all children were treated for anemia, fever, malaria, and caregiver reported diarrhea following the national health policy in Burkina Faso. Children with Hb ≤ 80 g/L received iron supplements (ferrous sulfate, 2–6 mg iron/kg body weight/d for 30 days, depending on the anemia severity) and 200 mg mebendazole/d for three days to treat possible helminthic infections. Children with a positive rapid diagnostic test (RDT) for malaria received malaria treatment for three days (amodiaquine-artesunate, 1 tablet/d) and an antipyretic (paracetamol, 1/2 tablet/d for three days), and children with confirmed fever and a negative RDT and no other clinical symptoms received paracetamol only for three days. Oral rehydration salts (ORS: 1 sachet/d for 4 days) were given to children with reported diarrhea. Caregivers in the IC were advised to start the supplementation even during illness.

Biochemistry subgroup
A subset of 1065 children from the IC and NIC were randomly selected for the biochemistry subgroup and asked to provide a venous blood sample as described below. The biochemistry subgroup included only one child from a concession to avoid reduced accuracy of estimation due to intra-cluster correlation, and excluded children with reported fever or diarrhea symptoms on the day of enrollment or on the scheduled blood collection day. Children were enrolled in the biochemistry subgroup until the target sample size was reached. This paper reports on data obtained from children who successfully provided blood specimens at both 9 and 18 months for analyses of micronutrient status.

Sample size for the biochemistry subgroup
The sample size estimate for the micronutrient status assessment was based on the number of children needed in each group to detect differences in effect size of 0.6 SDs with a significance of \( p \leq 0.05 \) and power \( \geq 0.80 \) for group-wise comparisons of pZC among the means of five groups (the four intervention groups and the NIC), consistent with the magnitude of effect reported in previous zinc supplementation trials [10, 25]. The estimated sample size for the NIC was inflated for an assumed design effect of 1.5 due to the cluster sampling design, resulting in an estimated total sample requirement of 374 children in the 5 groups (68 in each of the 4 intervention groups and 102 in the NIC). This target sample size was increased to a total of 468 children in the 5 groups to allow for 20% attrition.

**Anthropometry**
When the children were 9 months of age, their length was measured to the nearest 0.1 cm (Seca Model 417, Hamburg, Germany), and their weight was assessed with 50 g precision (Seca Model 383). The mothers’ height (Seca Model 217) and weight (Seca Model 874) were assessed during the same visit. Measurements were carried out in duplicate by one of four trained and standardized anthropometrists and their assistants. A third measurement was carried out in case of a disagreement between the two first measurements of >0.5 cm for length/height and >0.1 kg for weight. The average of the two closest values was used in the statistical analysis.

**Household demographics and child feeding and morbidity data**
Data on maternal education and marital status were collected at enrollment. At 9 and 18 months, 24-h and 7-day recall data on food intake frequencies and breastfeeding patterns were collected for all children. After enrollment, children in the IC were visited weekly by trained field agents who delivered the supplements and collected data on adherence to supplementation [24], general health status and morbidity symptoms [23]. Treatment was provided in case of reported diarrhea, reported or confirmed fever, and confirmed malaria, as described above. Data on high-dose vitamin A supplementation was collected by the field agents on a monthly basis. The field agent showed a picture of a high-dose vitamin A capsule during the interview to help the mother recognize it and distinguish it from the oral polio vaccine.

**Capillary blood hemoglobin and zinc protoporphyrin concentrations**
At the time of enrollment screening, Hb was measured in a capillary blood specimen, using a Hemocue device (model Hb 201+, Angelholm, Sweden), and 300 μL capillary blood was collected in microcuvettes containing lithium heparin (CB 300 LH, Sarstedt AG & Co, Nümbrecht, Germany) and stored in a cold-box for subsequent analysis of zinc protoporphyrin (ZPP) [26], as described below.

**Venous blood collection and processing**
Trained phlebotomists also obtained 5 mL blood from an antecubital or metacarpal vein from children in the biochemistry subgroup. The venous specimen was collected into trace element-free lithium heparin vacutainer tubes (Sarstedt AG & Co, Nümbrecht, Germany) 1–2 h after the last breastfeeding episode, using the specimen collection and processing methods recommended by the International Zinc Nutrition Consultative Group [4]. Blood samples were stored in a cold-box and transported to the field laboratory for processing and/or analysis. At the field
laboratory, plasma was separated from whole blood by centrifuging at 2800 rpm for 10 min. For analysis of pZC, iron status indicators, retinol-binding protein (RBP) and acute phase proteins [C-reactive protein (CRP) and α-1-acid glycoprotein (AGP)], plasma was stored at −20 °C until shipment to the collaborating laboratories for analysis.

Laboratory analyses
PZC was measured using an inductively coupled plasma optical emission spectrophotometer (Vista; Varian Inc, Walnut Creek, CA) at the Children’s Hospital of Oakland Research Institute [27, 28]. Inter- and intra-run coefficients of variation (CV) of control serum were 2.3% and 1.7%, respectively. Indicators of iron status [plasma ferritin (pF), soluble transferrin receptor (sTfR)] and vitamin A status [RBP], and acute phase proteins [CRP and AGP] were analyzed by ELISA (DBS-Tech in Willstaett, Germany) [29]. The CVs of the different indicators for a pooled plasma sample were 3.3%, 2.0%, 3.3%, 4.4% and 5.5% for pF, sTfR, RBP, CRP and AGP, respectively. Retinol (ROH) concentration was measured in a subset of randomly selected samples by using high performance liquid chromatography (HPLC, Agilent 1100) at the University of California, Davis, using a slight modification of the method described by Bieri et al. [30]. The CV of a control sample run in triplicate with each batch of plasma ROH samples was 2.6% within the same run and 2.7% between runs. ZPP was assessed in capillary blood samples at the field laboratory using a hemato-fluorometer (206D, AVIV Biomedical Inc., Lakewood, NJ, USA) after a maximum of 4 days of storage in the refrigerator, during which ZPP is considered stable [31]. Samples were analyzed in duplicate, unless inadequate volume only allowed for one measurement.

Validation of the RBP cutoff for vitamin A deficiency
Cutoffs for determining vitamin A deficiency based on RBP differ among populations [32], so we determined a cutoff for our study population by measuring both ROH and RBP concentrations in a subset of 40 randomly selected samples. Logarithm-transformed ROH values were tested for their correlation with logarithm-transformed RBP values from the same child at the same age using the Pearson correlation test, and a linear regression was generated (Proc GLM). There was a high correlation between ROH and RBP measured in the 40 samples ($R = 0.78$, $p < 0.0001$). To derive the corresponding RBP cutoff for vitamin A deficiency, a regression model used was:

$$\text{Log ROH} = -0.30 + 0.87 \times \text{Log RBP}.$$  

In this population, the RBP cutoff corresponding to 0.70 μmol ROH/L is 0.94 μmol RBP/L. The sensitivity of this population-adjusted cutoff to detect low ROH (<0.70 μmol/L) was 82% and the specificity was 83%.

Data analysis
All statistical analyses were carried out using SAS software for Windows (9.3, SAS Institute, Cary, North Carolina). Descriptive statistics (means, geometric means (95% confidence interval) and proportions) were used to assess baseline information by group, and to compare children included in the biochemistry subgroup with those not included. Variables that were not normally distributed were transformed using Box-Cox transformations to find the optimal transformation. Analysis was done with logarithm-transformed variables, which were back transformed for reporting of descriptive results.

Plasma concentrations of zinc, pF, sTfR and RBP and capillary whole blood ZPP were adjusted categorically for the presence of inflammation [33]. Participants were stratified into four inflammation categories based on elevation of one or both acute phase proteins, or no inflammation using the method described by Thurnham et al. [33], and cutoffs of 5 mg/L for CRP and 1 g/L for AGP. Body iron stores (BIS) were calculated using the ratio of both adjusted and unadjusted sTfR and pF concentrations using the formula developed by Cook et al. [34]. Micronutrient deficiencies were defined using the following cutoffs, for both adjusted and unadjusted values: zinc deficiency (pZC <65 μg/dL) [4], anemia (Hb <110 g/L) [35], iron deficiency [ID, pF <12 μg/L] [36], sTfR >8.3 mg/L, BIS <0 mg/kg, and ZPP >70 μmol/mol heme [37], and vitamin A deficiency (RBP <0.94 μmol/L). Additionally, iron deficiency anemia (IDA) was defined as having both anemia and ID, as outlined above.

Length-for-age z-score (LAZ) and weight-for-length z-score (WLZ) were calculated in relation to the World Health Organization Child Growth Standards using SAS macros [38]. Breastfeeding and 24 h-complementary feeding indicators were constructed according to World Health Organization guidelines [39]. 7-day intake of vitamin-A rich fruits and vegetables were summarized as continuous scores ranging from 0 to 7. Consumption frequencies of vitamin A-rich fruits and vegetables were also categorized dichotomously (<3 or ≥3 d/week). Definitions of infectious diseases identified in IC children are reported in more detail elsewhere [22, 23]. Briefly, diarrhea was defined as caregiver report of three or more liquid or semi-liquid stools during a 24-h period. An episode of diarrhea was defined as the period starting the day the child first had diarrhea preceded and followed by a two-day, diarrhea-free period. Fever was defined as any fever reported by the caregiver or elevated auricular temperature (>37.5 °C), as measured by the field workers. An episode of fever was defined as the period starting the day the child first had fever preceded and followed by two days when the child had not had fever. Malaria was defined as the presence of reported or confirmed fever during the 24 h preceding the morbidity.
visit, associated with a positive RDT. An episode of malaria was defined as the presence of a new episode of reported or confirmed fever and a positive malaria RDT obtained >21 days after a previously treated malaria episode.

Outcomes for inflammation, zinc, iron and vitamin A status and changes in the outcomes between baseline and at 18 months were compared by intervention group and cohort using analysis of covariance for continuous outcome variables and logistic regression for dichotomous variables. Differences in the outcomes between baseline and at 18 months were tested using repeated measurement of covariance for continuous outcomes and the random statement of the logistic regression for dichotomous variables. Analysis included a random effect of the community to account for intra-community correlation. Intervention group and cohort were used as the main effects, and covariates were tested individually in a binary model with the outcome before including the variables with $p < 0.1$ in the final model. All the outcomes were adjusted for baseline values. Covariates tested were previously listed in our plan of analysis, which was written before the study code was broken, and included child age, sex, baseline anthropometric characteristics and maternal and household characteristics, study season and 18 months acute phase proteins. Indicators of iron status and RBP were adjusted additionally for baseline RDT, iron supplementation and breastfeeding and 24-h complementary feeding indicators. Covariates which were significantly associated with the outcome were tested for their potential modifying effect of the intervention groups and cohort. We also tested baseline pZC for its potential modifying effect of the intervention cohort and group, and recent high-dose vitamin A supplementation of the intervention groups on RBP at 18 months within the IC. Intervention group means were compared post-hoc using least-square means with the Tukey-Kramer test. Tables report the comparison among the four intervention groups and between the combined intervention groups and the non-intervention cohort (IC vs. NIC). Additional 5-group comparisons were conducted and reported only when deemed helpful to clarify subtle differences in the results.

**Results**

**Baseline characteristics**

Among the 1065 children randomly selected for possible participation in the biochemistry sub-group, 66% ($n = 701$) were eligible on the scheduled day (i.e. free of symptomatic diarrhea and fever, as reported by the caregiver). Among the eligible children, a venous blood sample was successfully collected in 60% ($n = 414$) at 9 months. Among those, 404 children successfully provided blood samples at both 9 and at 18 months and are included in this analysis (Fig. 1).

Children who provided venous blood samples did not differ from those who did not, except that a higher proportion of the children who provided samples had a positive initial RDT (67 vs. 61% respectively, $p = 0.015$). At baseline, 23% of children in the biochemistry subgroup were stunted, 32% were underweight and 18% were wasted. Anemia prevalence was high, affecting 93% of children in the biochemistry subgroup. At enrollment, one-third of the children had Hb concentration <80 g/L and received iron supplementation and antihelmithic treatment, and two-thirds were treated for positive malaria RDT. All children were still breastfed, and almost all children had started eating some type of complementary food. In particular, 83% of children reported to receive cereal-based foods and only 7% and 13%, respectively, consumed legumes and flesh food on the previous day (Table 1).

**Inflammation indicators**

At baseline, 4% of children had elevated CRP only, 33% had both elevated CRP and AGP and 30% had elevated AGP only, with no significant differences among the intervention groups or cohorts. Mean AGP and CRP concentrations at 18 months did not differ significantly by intervention cohort or by intervention group within the IC. Compared to the NIC, the IC had a lower prevalence of children who had elevated CRP only and both elevated CRP and AGP, and a greater proportion of children who had elevated AGP only at 18 months (2, 27 and 31%, respectively for IC children compared to 5%, 37% and 23% for NIC children, $p = 0.03$), but the total percentage of children with inflammation remained high for both cohorts at 18 months.

**Plasma zinc concentration**

At baseline, 35% of the children had low pZC after adjustment for inflammation. The proportion of children with low pZC increased from 9 to 18 months ($p < 0.0001$), but did not differ among the intervention groups or between the cohorts at 18 months (Table 2). From 9 to 18 months, mean pZC decreased significantly from 67.1 to 63.6 µg/dL in the NIC and from 69.5 to 64.8 µg/dL in the IC ($p < 0.0001$). The change in pZC was not significantly different between the two cohorts ($p = 0.39$), nor by intervention group ($p = 0.84$). AGP and CRP were significantly associated with pZC at 18 months, but did not modify the effect of intervention group or cohort on final pZC.

**Hemoglobin concentration**

At baseline, the mean Hb concentration for all groups combined was 88 g/L, and 93% of the children were anemic. At 18 months, the prevalence of anemia decreased by one-fifth in the IC, but did not change in the NIC (Tables 3 and 4). Nevertheless, 74% of the children in
the IC remained anemic, and there were no significant differences among the four intervention groups.

The presence of inflammation and study season were significantly associated with final Hb concentration, but only the study season modified the effect of intervention group and cohort on final Hb. In particular, Hb concentration increased significantly in IC children who spent ≥5 months in the study during the rainy season (96 g/L in the IC vs. 82 g/L in NIC, \( p = 0.0003 \)), while the Hb response did not differ significantly in children who participated in the study mostly during the dry season (99 g/L in IC vs. 95 g/L in NIC, \( p = 0.86 \)).

### Iron status

Iron status indicators were affected by the presence of inflammation (Tables 3 and 4), so the results are presented after adjusting for these effects. The estimated prevalence of iron deficiency differed by iron status indicator. In particular, at 9 months, 25% of the children had low adjusted pF, 90% had high adjusted sTfR, 56% had low adjusted BIS and 96% had high adjusted ZPP. 24% of children had IDA as defined by the simultaneous presence of anemia and low adjusted pF, and 85% had IDA as defined by anemia and elevated adjusted sTfR.

There was no effect of supplementing different amounts and sources of zinc on any of the iron status indicators except for pF and BIS. Children who received LNS-Zn10 had a lower adjusted geometric mean pF and BIS compared to LNS-Zn5 (22.1 μg/L vs. 30.5 μg/L, \( p = 0.034 \) for pF; and 2.21 mg/kg vs. 3.35 mg/kg, \( p = 0.047 \) for BIS), although the prevalence of low adjusted pF and low adjusted BIS was not significantly different among intervention groups. In a 5-group analysis, adjusted geometric mean pF of children who received LNS-Zn10 was not significantly different from children in the NIC (\( p = 0.298 \)).

The prevalence of ID at 18 months, as defined by adjusted pF, was significantly different between the two cohorts (\( p < 0.0001 \)). In particular, the prevalence of ID

### Table 1

Child, maternal and household characteristics of study participants assessed for biochemical status, by study group

|                  | LNS-Zn0 | LNS-Zn5 | LNS-Zn10 | LNS-TabZn | NIC | \( p \)-value for the difference among 5 groups\(^{ab} \) |
|------------------|---------|---------|----------|-----------|-----|-----------------------------------------------|
| N (children with 9 and 18 mo values) | 84      | 75      | 79       | 73        | 93  |                                               |
| N boys (%)       | 38 (45.2) | 41 (54.7) | 31 (39.2) | 38 (52.0) | 40 (49.5) | 1.000 |
| Baseline child LAZ | \(-1.29 \pm 1.00\) | \(-1.25 \pm 1.04\) | \(-1.14 \pm 1.08\) | \(-1.11 \pm 1.10\) | \(-1.14 \pm 1.08\) | 0.783 |
| Baseline child WLZ | \(-1.03 \pm 1.20\) | \(-0.92 \pm 1.04\) | \(-1.13 \pm 0.91\) | \(-0.86 \pm 1.05\) | \(-1.05 \pm 1.11\) | 0.506 |
| N Baseline iron supplementation (%)\(^c\) | 20 (23.8) | 21 (28.0) | 21 (26.6) | 23 (31.5) | 29 (31.2) | 0.828 |
| N Baseline RDT positive (%) | 62 (73.8) | 49 (65.3) | 54 (68.3) | 47 (64.4) | 58 (62.4) | 0.479 |
| Maternal body mass index (kg/m\(^2\)) | 20.5 ± 1.7 | 20.8 ± 2.3 | 21.1 ± 2.6 | 21.0 ± 2.3 | 20.4 ± 2.3 | 0.164 |
| Maternal education |                                               |                                               |                                               |                                               | 0.383 |
| No formal or informal education | 53 (63.1) | 47 (62.7) | 51 (64.6) | 43 (58.9) | 68 (73.1) |                                               |
| Any informal education and/or less than one year of formal education | 24 (28.6) | 21 (28.0) | 19 (24.0) | 18 (24.7) | 17 (18.3) |                                               |
| At least one year of formal education | 7 (8.3) | 7 (9.3) | 9 (11.14) | 12 (16.4) | 8 (8.6) |                                               |
| Baseline child feeding practices |                                               |                                               |                                               |                                               |                                               |
| Child still breastfed (%) | 84 (100) | 75 (100) | 79 (100) | 73 (100) | 93 (100) | 1.000 |
| Animal source food\(^d\) | 21 (25.0) | 18 (24.0) | 15 (19.0) | 22 (30.1) | 22 (23.7) | 0.621 |
| Child morbidity during the intervention\(^e\) |                                               |                                               |                                               |                                               |                                               |
| Child malaria incidence (episodes per 100 child days at risk) | 0.60 ± 0.48 | 0.62 ± 0.53 | 0.58 ± 0.48 | 0.64 ± 0.54 | – | 0.339 |
| Child fever incidence (episodes/100 child-days at risk) | 1.28 ± 0.84 | 1.34 ± 0.94 | 1.51 ± 1.19 | 1.39 ± 0.95 | – | 0.683 |
| Child diarrhea incidence (episodes per 100 child days at risk) | 1.02 ± 0.90 | 0.82 ± 0.66 | 0.92 ± 0.80 | 0.92 ± 0.92 | – | 0.469 |

\(^{a}\)Values presented are means ± SD, \( n \) (\%)  
\(^{b}\)\( P \)-values are from mixed model for continuous variables, logistic regression for binary variables and Chi square for polychotomous variables. All analyses were adjusted for the random effect of village, and in morbidity outcomes, were controlled for over-dispersion  
\(^{c}\)Children with Hb <80 g/L received ferrous sulfate, 2–6 mg iron/kg body weight/d for 30 days, depending on the anemia severity and 200 mg mebendazole/d for three days to treat possible helminthic infections  
\(^{d}\)Child consumed at least one animal-source food during the previous 24 h  
\(^{e}\)Morbidity outcomes include children in the IC who provided data on ≥30 days

LAZ length for age z-score, WLZ weight for length z-score

---

Abbeddou et al. BMC Pediatrics (2017) 17:46 Page 7 of 17
Table 2  Effects of SQ-LNS containing different amounts and sources of zinc provided along with malaria and diarrhea treatment on plasma zinc concentration and prevalence of low plasma zinc concentration in children at 9 and 18 months, by study group

|                        | LNS-Zn0 | LNS-Zn5 | LNS-Zn10 | LNS-TabZn5 | \( P \)-value among 4 intervention groups\(^{a,b} \) | IC  | NIC  | \( P \)-value between cohorts\(^{a,b} \) | ICC  | DE  |
|------------------------|---------|---------|----------|------------|-------------------------------------------------|-----|------|-------------------------------------|------|-----|
| **Plasma zinc concentration (\( \mu g/dL \))\(^{e} \)** |         |         |          |            |                                                 |     |      |                                     |      |     |
| N (9 and 18 mo)        | 84      | 74      | 79       | 73         | 0.255                                            | 310 | 93   | 0.078                               | 0.00 | 1.0 |
| Unadjusted pZC at 9 months | 66.2 (63.4, 69.0) | 66.0 (63.5, 68.6) | 68.9 (66.5, 71.3) | 68.8 (65.8, 72.0) |                                                  |     |      |                                     |      |     |
| Adjusted pZC at 9 months | 68.0 (65.2, 70.9) | 68.1 (65.6, 70.8) | 71.0 (68.6, 73.5) | 71.2 (68.1, 74.5) | 0.212                                            |     |      |                                     |      |     |
| Unadjusted pZC at 18 months | 61.7 (59.2, 64.4) | 62.5 (60.1, 65.0) | 64.4 (61.9, 67.0) | 64.5 (62.4, 66.6) | 0.774                                            |     |      |                                     |      |     |
| Adjusted pZC at 18 months | 63.3 (60.7, 65.9) | 64.2 (61.8, 66.7) | 66.0 (63.5, 68.7) | 65.9 (63.8, 68.1) | 0.742                                            |     |      |                                     |      |     |
| Change in adjusted pZC\(^{f} \) | −49 (−69.3, −27.8) | −4.0 (−65.8, −1.41) | −4.8 (−7.46, −2.13) | −6.0 (−8.89, −3.05) | 0.843                                            |     |      |                                     |      |     |
| % Low plasma zinc concentration (pZC < 65 \( \mu g/dL \))\(^{f} \)** |         |         |          |            |                                                 |     |      |                                     |      |     |
| Low unadjusted pZC at 9 months, N (%) | 38 (45.3) | 34 (45.9) | 28 (35.4) | 33 (45.2) | 0.498                                            | 133 (42.9) | 44 (47.3) | 0.399                               | −     | −     |
| Low adjusted pZC at 9 months, N (%) | 29 (34.5) | 28 (37.8) | 22 (27.8) | 27 (37.0) | 0.587                                            | 106 (34.2) | 36 (38.7) | 0.370                               | −     | −     |
| Low unadjusted pZC at 18 months, N (%) | 53 (63.1) | 46 (62.2) | 46 (58.2) | 39 (53.4) | 0.909                                            | 184 (59.3) | 56 (60.2) | 0.379                               | −     | −     |
| Low adjusted pZC at 18 months, N (%) | 50 (59.5) | 42 (56.8) | 43 (54.4) | 34 (46.6) | 0.723                                            | 169 (54.5) | 51 (54.8) | 0.425                               | −     | −     |

**pZC plasma zinc concentration**

\(^{a}\)Geometric mean (95% confidence interval), n (%). Values in the same row with different superscript letters are significantly different (\( P < 0.05 \))

\(^{b}\)Adjusting for the random effect of the village and baseline value

\(^{c}\)Inter-cluster coefficient calculated based on the cluster (village) variance and the residual variance from proc MIXED

\(^{d}\)Design effect calculated based on the standard error of the intervention with or without the random effect of the cluster

\(^{e}\)pZC adjusted for time of blood draw, time since last breastfeed and CRP and AGP concentration; and additionally for baseline value at 18 months

\(^{f}\)Means (95% CI) were calculated based on non-transformed adjusted values, but covariance analysis was done with the logarithmic-transformed variable
Table 3 Effect of SQ-LNS containing different amounts and sources of zinc provided along with malaria and diarrhea treatment on hemoglobin concentration and iron status indicators among children 9–18 months of age, by study group

|                     | LNS-Zn0 | LNS-Zn5 | LNS-Zn10 | LNS-TabZn5 | P-value among 4 intervention groups | ICC | NIC | P-value between cohorts |
|---------------------|---------|---------|----------|------------|-------------------------------------|-----|-----|------------------------|
| Hemoglobin (g/L) a, e |         |         |          |            |                                     |     |     |                        |
| N (9 and 18 months) | 80      | 73      | 76       | 68         | 297                                 | 87  |     |                        |
| Hb at 9 months      | 89 ± 15 | 87 ± 14 | 88 ± 16  | 89 ± 15    | 0.0925                              | 88 ± 15 | 88 ± 16 | 0.0805 | 0.02 | 1.3 |
| Hb at 18 months     | 97 ± 17 | 96 ± 15 | 98 ± 16  | 98 ± 15    | 0.0731                              | 97 ± 16 | 90 ± 15 | 0.0003 | 0.04 | 1.5 |
| Plasma ferritin (μg/L) f |         |         |          |            |                                     |     |     |                        |
| N (9 and 18 months) | 84      | 75      | 79       | 73         | 311                                 |     |     |                        |
| Unadjusted pF at 9 months | 35.9 (29.6, 43.4) | 29.7 (24.9, 35.4) | 34.1 (28.5, 40.9) | 33.0 (26.5, 41.1) | 0.127 | 33.2 (30.2, 36.5) | 27.4 (23.3, 32.3) | 0.096 | 0.00 | 1.0 |
| Adjusted pF at 9 months | 23.1 (19.4, 27.4) | 18.5 (15.7, 21.8) | 21.6 (18.2, 25.5) | 19.7 (16.3, 23.8) | 0.016 | 20.7 (19.0, 22.6) | 17.0 (14.6, 19.8) | 0.038 | 0.00 | 1.0 |
| Unadjusted pF at 18 months | 44.6 (36.3, 54.7) | 47.7 (38.9, 58.5) | 34.0 (28.7, 40.2) | 42.0 (34.0, 52.1) | 0.0023 | 41.7 (37.8, 46.0) | 27.0 (22.3, 32.8) | <0.0001 | 0.04 | 1.5 |
| Adjusted pF at 18 months | 29.5 (24.9, 35.0) | 30.5 (25.2, 36.8) | 22.1 (18.5, 264) | 28.6 (23.3, 35.0) | 0.016 | 27.4 (25.0, 30.0) | 16.9 (14.3, 19.9) | <0.0001 | 0.06 | 1.8 |
| Soluble transferrin receptor (mg/L) g |         |         |          |            |                                     |     |     |                        |
| N (9 and 18 months) | 84      | 75      | 79       | 73         | 311                                 |     |     |                        |
| Unadjusted sTfR at 9 months | 17.8 (15.8, 200) | 197 (17.7, 22.0) | 184 (16.5, 204) | 184 (14.7, 186) | 0.286 | 181 (17.1, 191) | 166 (148, 18.7) | 0.385 | 0.03 | 1.4 |
| Adjusted sTfR at 9 months | 15.7 (14.0, 176) | 174 (15.7, 194) | 162 (14.6, 180) | 144 (12.9, 161) | 0.162 | 159 (15.1, 168) | 146 (130, 163) | 0.270 | 0.03 | 1.4 |
| Unadjusted sTfR at 18 months | 8.8 (8.1, 96) | 91 (83.3, 99) | 9.0 (83.9, 98) | 9.2 (84.100) | 0.086 | 9.0 (86.94) | 11.9 (109, 13.0) | <0.0001 | 0.01 | 1.1 |
| Adjusted sTfR at 18 months | 7.8 (7.2, 85) | 80 (73, 87) | 80 (73, 86) | 82 (75, 89) | 0.0828 | 80 (77.83) | 106 (97, 11.5) | <0.0001 | 0.00 | 1.0 |
| Body iron stores (mg/kg) h |         |         |          |            |                                     |     |     |                        |
| N (9 and 18 months) | 84      | 75      | 79       | 73         | 311                                 |     |     |                        |
| Unadjusted BIS at 9 months | 1.06 (0.23, 188) | 0.00 (-0.75, 075) | 0.76 (0.06, 147) | 1.02 (0.18, 186) | 0.069 | 0.72 (0.33, 1.10) | 0.34 (-0.37, 1.05) | 0.521 | 0.01 | 1.1 |
| Adjusted BIS at 9 months | -0.08 (-08-40, 72) | -1.25 (-1.98, -052) | -0.44 (-1.13, 029) | -0.35 (-1.14, 044) | 0.120 | -0.52 (-0.89, -14) | -0.91 (-1.60, -0.22) | 0.401 | 0.01 | 1.1 |
| Unadjusted BIS at 18 months | 4.37 (3.64, 510) | 451 (3.69, 534) | 3.30 (2.57, 403) | 4.02 (3.19, 484) | 0.025 | 4.05 (3.67, 443) | 1.48 (0.76, 2.19) | <0.0001 | 0.05 | 1.7 |
| Adjusted BIS at 18 months | 3.31 (266, 397) | 3.35 (25.6, 414) | 2.21 (1.44, 2.98) | 3.04 (225, 383) | 0.019 | 2.98 (261, 335) | 0.22 (-0.44, 0.88) | <0.0001 | 0.06 | 1.8 |
| Zinc protoporphyrin (μmol/mol heme) i |         |         |          |            |                                     |     |     |                        |
| N (9 and 18 months) | 81      | 73      | 79       | 73         | 306                                 |     |     |                        |
| Unadjusted ZPP at 9 months | 212 (184, 244) | 235 (206, 269) | 208 (186, 233) | 202 (177, 230) | 0.703 | 214 (200, 228) | 198 (169, 233) | 0.0646 | 0.10 | 2.2 |
| Adjusted ZPP at 9 months | 193 (167, 223) | 212 (185, 242) | 188 (169, 210) | 180 (158, 204) | 0.574 | 193 (181, 206) | 180 (154, 210) | 0.625 | 0.09 | 2.1 |
Table 3 Effect of SQ-LNS containing different amounts and sources of zinc provided along with malaria and diarrhea treatment on hemoglobin concentration and iron status indicators among children 9–18 months of age, by study group (Continued)

|                               | Unadjusted ZPP at 18 months | Adjusted ZPP at 18 months | Hb | pF | sTfR | ZPP |
|-------------------------------|----------------------------|--------------------------|----|----|------|-----|
|                               | 144 (129, 161)              | 132 (118, 148)           |    |    |      |     |
|                               | 151 (137, 168)              | 137 (124, 151)           |    |    |      |     |
|                               | 151 (132, 159)              | 132 (122, 144)           |    |    |      |     |
|                               | 145 (132, 156)              | 133 (121, 145)           |    |    |      |     |
|                               | 0.920                       | 0.946                    |    |    |      |     |
|                               | 146 (139, 153)              | 133 (127, 140)           |    |    |      |     |
|                               | 203 (184, 225)              | 182 (164, 203)           |    |    |      |     |

Hb: hemoglobin concentration, pF: plasma ferritin, sTfR: soluble transferrin receptor, ZPP: zinc protoporphyrin

aAdjusted means ± standard deviation, and geometric mean (95% confidence interval); all such values

bValues in a row with superscripts with different letters differ P < 0.05 using Proc MIXED. Values are adjusted for the random effect of the village

cInter-cluster coefficient calculated based on the cluster (village) variance and the residual variance from proc MIXED

dDesign effect calculated based on the standard error of the intervention with or without the random effect of the cluster

eHb values adjusted for AGP, CRP, and at 18 months, adjusted additionally for baseline value and study season

f pF values adjusted for AGP, CRP, and at 18 months, adjusted additionally for baseline value, baseline iron supplementation, RDT, maternal BMI and study season

gsTfR values adjusted for AGP, CRP, age and sex; and at 18 months, adjusted additionally for baseline value, baseline iron supplementation, study season, and minimum meal frequency

hZPP values adjusted for AGP, CRP and sex; and at 18 months, adjusted additionally for baseline value, baseline iron supplementation, maternal BMI, study season, and animal food source
Table 4  Effect of SQ-LNS containing different amounts and sources of zinc along with malaria and diarrhea treatment on prevalence of anemia, iron deficiency and iron deficiency anemia in children aged 9 – 18 months

|                      | LNS-Zn0 | LNS-Zn5 | LNS-Zn10 | LNS-TabZn5 | P-value among 4 intervention groups | IC   | NIC   | P-value between cohorts |
|----------------------|---------|---------|----------|------------|-------------------------------------|------|-------|------------------------|
| % Anemia (Hb <110 g/L) a |         |         |          |            |                                     |      |       |                        |
| At 9 months, N (%)   | 76 (95.0) | 69 (94.5) | 72 (94.7) | 62 (91.2)  | 0.794                               | 279 (93.9) | 80 (91.9) | 0.515                  |
| At 18 months, N (%)  | 62 (77.5) | 57 (78.1) | 52 (68.4) | 48 (70.6)  | 0.503                               | 219 (73.7) | 80 (91.9) | 0.0007                 |
| % Low plasma ferritin (pF <12 μg/L) |         |         |          |            |                                     |      |       |                        |
| Low unadjusted pF at 9 months, N (%) | 12 (14.3) | 10 (13.3) | 9 (11.4)  | 10 (13.7)  | 0.950                               | 41 (13.2) | 11 (11.8) | 0.575                  |
| Low adjusted pF at 9 months, N (%) | 18 (21.4) | 25 (33.3) | 12 (15.2) | 17 (23.3)  | 0.049                               | 72 (23.1) | 29 (31.2) | 0.126                  |
| Low unadjusted pF at 18 months, N (%) | 4 (4.8)  | 2 (2.7)  | 6 (7.6)  | 6 (8.2)  | 0.476                               | 18 (5.8) | 19 (20.4) | <0.0001                |
| Low adjusted pF at 18 months, N (%) | 9 (10.7) | 6 (8.0)  | 16 (20.2) | 11 (15.1) | 0.109                               | 42 (13.5) | 30 (32.3) | 0.0001                 |
| % Elevated soluble transferrin receptor (sTfR >8.3 mg/L) |         |         |          |            |                                     |      |       |                        |
| High unadjusted sTfR at 9 months, N (%) | 77 (91.7) | 73 (97.3) | 75 (94.9) | 70 (95.9)  | 0.355                               | 295 (94.8) | 84 (90.3) | 0.100                  |
| High adjusted sTfR at 9 months, N (%) | 71 (84.5) | 71 (94.7) | 73 (92.4) | 69 (94.5)  | 0.080                               | 284 (91.3) | 79 (84.9) | 0.163                  |
| High unadjusted sTfR at 18 months, N (%) | 38 (45.2) | 37 (49.3) | 41 (51.9) | 36 (49.3)  | 0.884                               | 152 (48.9) | 70 (75.3) | 0.001                  |
| High adjusted sTfR at 18 months, N (%) | 31 (36.9) | 30 (40.0) | 35 (44.3) | 31 (42.5)  | 0.725                               | 127 (40.8) | 66 (71.0) | <0.0001                |
| % Low body iron stores (BIS <0 mg/kg) |         |         |          |            |                                     |      |       |                        |
| Low unadjusted BIS at 9 months, N (%) | 31 (36.9) | 37 (49.3) | 33 (41.8) | 29 (39.7)  | 0.260                               | 130 (41.8) | 38 (40.9) | 0.782                  |
| Low adjusted BIS at 9 months, N (%) | 37 (44.0)b | 50 (66.7)a | 44 (55.7)ab | 39 (53.4)ab | 0.049                               | 170 (54.7) | 58 (62.4) | 0.248                  |
| Low unadjusted BIS at 18 months, N (%) | 8 (9.5)  | 7 (9.3)  | 11 (13.9) | 11 (15.1)  | 0.641                               | 37 (11.9) | 31 (33.3) | 0.0001                 |
| Low adjusted BIS at 18 months, N (%) | 9 (10.7) | 15 (20.0) | 16 (20.3) | 16 (21.9)  | 0.385                               | 56 (18.0) | 43 (46.2) | <0.0001                |
| % Elevated capillary zinc protoporphyrin (ZPP >70 μmol/mol heme) |         |         |          |            |                                     |      |       |                        |
| High unadjusted ZPP at 9 months, N (%) | 78 (96.3) | 71 (97.3) | 79 (100.0) | 71 (97.3)  | 1.000                               | 299 (97.7) | 84 (91.3) | 0.968                  |
| High adjusted ZPP at 9 months, N (%) | 78 (96.3) | 71 (97.3) | 79 (100.0) | 71 (97.3)  | 1.000                               | 299 (97.7) | 84 (91.3) | 0.968                  |
| High unadjusted ZPP at 18 months, N (%) | 80 (98.8) | 71 (97.3) | 78 (98.7) | 72 (98.6)  | 0.844                               | 301 (98.4) | 92 (100.0) | 0.982                  |
| High adjusted ZPP at 18 months, N (%) | 80 (98.8) | 71 (97.3) | 78 (98.7) | 72 (98.6)  | 0.844                               | 301 (98.4) | 92 (100.0) | 0.982                  |
| Iron deficiency anemia |         |         |          |            |                                     |      |       |                        |
| % Low plasma ferritin and anemia |         |         |          |            |                                     |      |       |                        |
| Low unadjusted pF and anemia at 9 months, N (%) | 11 (13.8) | 10 (13.7) | 8 (10.5)  | 10 (14.7)  | 0.933                               | 39 (13.1) | 10 (11.5) | 0.632                  |
| Low adjusted pF and anemia at 9 months, N (%) | 15 (18.8) | 24 (32.9) | 11 (14.5) | 17 (25.0)  | 0.064                               | 67 (22.6) | 27 (31.0) | 0.130                  |
| Low unadjusted pF and anemia at 18 months, N (%) | 3 (3.8)  | 1 (1.4)  | 5 (6.6)  | 4 (5.9)  | 0.449                               | 13 (4.4) | 17 (19.5) | <0.0001                |
| Low adjusted pF and anemia at 18 months, N (%) | 8 (10.0) | 3 (4.1)  | 13 (17.1) | 8 (11.8)  | 0.067                               | 32 (10.8) | 25 (28.7) | 0.0002                 |
fell from 23% to 14% in the IC (a relative change of −42%), whereas it did not change in the NIC (Fig. 2). Similarly, the prevalence of ID, when defined by adjusted BIS, was significantly different between the two cohorts at 18 months and only fell significantly in the IC over the course of the study (Fig. 2). In contrast, the prevalence of elevated adjusted ZPP did not differ by cohort and increased from 96% to 99% (p = 0.01). The difference in prevalence of ID between IC and NIC was similar whether or not the indicators were adjusted for inflammation (Table 4). IDA was lower in both cohorts at 18 months, but decreased significantly only in the IC (IDA defined by pF decreased relatively by 51% in the IC vs. 7% in NIC, and IDA defined by sTfR decreased relatively by 63% in the IC vs. 16% in the NIC).

Vitamin A status
At baseline, adjusted RBP concentration did not differ by intervention group or cohort, with a geometric mean (95% confidence interval) of 0.97 (0.94, 1.00) μmol RBP/L. A total of 47% of the children had low adjusted plasma RBP concentrations at 9 months. Adjusted RBP concentration decreased more from 9 to 18 months in the NIC than in the IC (a relative change of −9 vs −4%, p = 0.014). Although the mean concentration at 18 months of, and the change in adjusted RBP was significantly different between the cohorts, the final prevalence of low RBP did not differ significantly (Table 5). Mean adjusted RBP at 18 months was not significantly different by intervention group (p = 0.056). RBP concentration at 18 months was significantly related to baseline RBP concentration, inflammation indicators, maternal education, and more frequent reported breastfeeding at 9 months, but none of these variables significantly modified the effects of intervention group or cohort.

At 18 months, 22% of children reportedly consumed vitamin A-rich fruits at least 3 days during the previous week, and none reportedly consumed vitamin A-rich fruits.

Table 4 Effect of SQ-LNS containing different amounts and sources of zinc along with malaria and diarrhea treatment on prevalence of anemia, iron deficiency and iron deficiency anemia in children aged 9 – 18 months (Continued)

| % Elevated soluble transferrin receptor and anemia                                      | 9–18 months | 71 (88.8) | 68 (93.2) | 68 (89.5) | 60 (88.2) | 0.656 | 267 (89.9) | 75 (86.2) | 0.667 |
|----------------------------------------------------------------------------------------|-------------|-----------|-----------|-----------|-----------|-------|-----------|-----------|-------|
| High unadjusted sTfR and anemia at 9 months, N (%)                                     |             | 67 (83.8) | 66 (90.4) | 66 (86.8) | 59 (86.8) | 0.427 | 258 (86.9) | 70 (80.5) | 0.490 |
| High adjusted sTfR and anemia at 9 months, N (%)                                      |             | 32 (40.0) | 29 (39.7) | 28 (36.8) | 27 (39.7) | 0.852 | 116 (39.1) | 63 (72.4) | 0.001 |
| High unadjusted sTfR and anemia at 18 months, N (%)                                   |             | 26 (32.5) | 24 (32.9) | 22 (28.9) | 24 (35.3) | 0.882 | 96 (32.3)  | 59 (67.8) | <0.0001 |
| High adjusted sTfR and anemia at 18 months, N (%)                                     |             |           |           |           |           |       |           |           |       |

Hb hemoglobin concentration, pF plasma ferritin, sTfR soluble transferrin receptor, ZPP zinc protoporphyrin
* Values in a row with superscripts with different letters differ P < 0.05, using Proc GLIMMIX. Values are adjusted for the cluster effect of the village.

Figure 2 Effect of SQ-LNS combined with malaria and diarrhea treatment on % relative change in prevalence of adjusted indicators of iron deficiency and anemia from 9 to 18 months of age in rural Burkinabe children. * Significantly different between the two cohorts (p < 0.05)
Table 5 Effect of SQ-LNS containing different amounts and sources of zinc provided along with malaria and diarrhea treatment on retinol binding protein concentrations and prevalence of low retinol binding protein concentrations in children at 9 and 18 months, by study group

| Retinol binding protein (μmol/L) | LNS-Zn0 | LNS-Zn5 | LNS-Zn10 | LNS-TabZn5 | P-value among 4 intervention groups\(^a,b\) | IC | NIC | P-value between cohorts\(^a,b\) | ICC\(^c\) | DE\(^d\) |
|----------------------------------|---------|---------|----------|------------|---------------------------------------------|----|-----|----------------------------------|--------|-------|
| N (9 and 18 mo)                  | 84      | 75      | 79       | 73         | 311                                          | 93 |      |                                  |        |       |
| Unadjusted RBP at 9 months       | 0.98 (0.91, 1.05) | 0.86 (0.79, 0.94) | 0.94 (0.88, 1.01) | 0.87 (0.81, 0.94) | 0.197                                        | 0.92 (0.88, 0.95) | 0.88 (0.82, 0.94) | 0.618 | 0.05 | 1.7 |
| Adjusted RBP at 9 months         | 1.04 (0.97, 1.12) | 0.93 (0.85, 1.01) | 1.01 (0.95, 1.08) | 0.95 (0.88, 1.02) | 0.171                                        | 0.98 (0.95, 1.02) | 0.94 (0.88, 1.00) | 0.555 | 0.05 | 1.7 |
| Unadjusted RBP at 18 months      | 0.86 (0.81, 0.92) | 0.86 (0.80, 0.92) | 0.92 (0.86, 0.98) | 0.95 (0.90, 1.00) | 0.044                                        | 0.89 (0.87, 0.92) | 0.79 (0.74, 0.84) | 0.004 | 0.03 | 1.4 |
| Adjusted RBP at 18 months        | 0.91 (0.86, 0.96) | 0.92 (0.86, 0.98) | 0.97 (0.91, 1.03) | 0.99 (0.94, 1.05) | 0.056                                        | 0.94 (0.92, 0.97) | 0.86 (0.81, 0.91) | 0.015 | 0.01 | 1.1 |

% Low retinol binding protein (RBP <0.94 μmol/L)\(^e\)

| N (9 and 18 months) | 84 | 75 | 79 | 73 | 311 | 93 |
|---------------------|----|----|----|----|-----|----|
| Low unadjusted RBP at 9 months, N (%) | 41 (48.8) | 44 (58.7) | 42 (53.2) | 48 (65.7) | 0.456 | 175 (56.3) | 53 (57.0) | 0.892 | – | – |
| Low adjusted RBP at 9 months, N (%) | 32 (38.1) | 40 (53.3) | 32 (40.5) | 38 (52.0) | 0.240 | 142 (45.7) | 48 (51.6) | 0.509 | – | – |
| Low unadjusted RBP at 18 months, N (%) | 54 (64.3) | 51 (68.0) | 45 (57.0) | 34 (46.6) | 0.028 | 184 (59.2) | 66 (71.0) | 0.052 | – | – |
| Low adjusted RBP at 18 months, N (%) | 46 (54.8) | 41 (54.7) | 36 (45.6) | 31 (42.5) | 0.280 | 154 (49.5) | 53 (57.0) | 0.332 | – | – |

RBP, retinol binding protein
\(^a\)Geometric mean (95% confidence interval), n (%). Values in the same row with different superscript letters are significantly different (P < 0.05)
\(^b\)Adjusting for the random effect of the village and baseline value
\(^c\)Inter-cluster coefficient calculated based on the cluster (village) variance and the residual variance from proc MIXED
\(^d\)Design effect calculated based on the standard error of the intervention with or without the random effect of the cluster
\(^e\)RBP adjusted for CRP and AGP concentrations; and at 18 months for baseline value, breastfeeding at baseline and women education
vegetables with this frequency. There was no relationship between reported consumption of vitamin A rich fruits and RBP concentration. Twelve percent of children in the IC reportedly received a high-dose vitamin A supplement during the month preceding the biochemistry visit at 18 months. However, reported receipt of high-dose vitamin A supplement was not associated with RBP concentration at 18 months. Similarly, RBP concentration at 18 months was not significantly related to baseline pZC, and pZC did not modify the effect of intervention group or cohort on final RBP concentration.

**Discussion**

Different amounts of zinc provided either in SQ-LNS or as a dispersible zinc tablet did not affect the final pZC or other markers of micronutrient status, except for the lower final mean pF concentration and lower BIS in children who received LNS-Zn10 compared to those who received LNS-Zn5. By contrast, SQ-LNS, provided along with malaria and diarrhea treatment in the intervention cohort, increased the children's final iron status, Hb concentration and vitamin A status, compared with those in the non-intervention cohort. The intervention package also reduced the prevalence of iron deficiency, anemia and IDA, compared with the NIC, although most children remained anemic at 18 months. Hb concentration increased significantly more among children in the IC who participated in the study mostly during the rainy season, when food is generally less available and malaria and diarrhea are more common, suggesting that the benefit may be greatest during periods of food insecurity and/or more frequent infections.

One third of children had subclinical zinc deficiency at baseline and more than half of all children had subclinical zinc deficiency at endline. Thus, zinc deficiency is a public health concern in the study population [40]. Nevertheless, the lack of a change in pZC after zinc supplementation with the dispersible tablet differs from the results of multiple other studies [10], including a short-term study completed in the same geographic region in which supplements were given under direct observation and produced a sizeable increase in pZC [28]. The lack of change in pZC among children supplemented with zinc tablets in the present study could indicate low adherence to supplementation with tablets or failure to provide the tablets between meals. In fact, we have previously reported that tablet adherence was less than 30% in a subgroup of children who were observed for 12 h at home; and more than half of the time, the tablet was given less than 30 min after either a meal or SQ-LNS had been served, contrary to what was recommended according to the study protocol [24]. The lack of change in pZC among children who received additional zinc through SQ-LNS is consistent with results from most previous trials that provided supplemental zinc mixed with food [19, 41–43]. Zinc provided with food is presumably less well absorbed than when provided as a tablet or syrup apart from meals, or the absorbed zinc is metabolized differently post-absorption.

Zinc supplementation had no effect on Hb concentration and anemia prevalence, regardless of the dose or form of supplementation. This is in agreement with a meta-analysis of zinc supplementation trials, which found that daily zinc supplementation (10–20 mg) among children <15 years of age had no effect on Hb concentration [44]. Zinc supplementation also had no effect on most iron status indicators except for the lower pF concentration and lower BIS found in children who received LNS-Zn10, possibly due to inhibition of iron absorption in the presence of higher amounts of zinc. Nevertheless, iron status was increased by concurrent supplementation of zinc and iron despite the slightly smaller magnitude of response with the higher dose of zinc [10, 11].

Provision of supplemental zinc did not significantly affect the final prevalence of vitamin A deficiency or mean adjusted RBP at 18 months. Previous studies on the impact of adding zinc to vitamin A supplements on vitamin A status have yielded inconsistent results [12–14]. Smith suggested that the effect of zinc on response to vitamin A supplementation may be conditioned by the severity of zinc deficiency [45]. This was not confirmed in our study. Although zinc deficiency was a public health concern in the study population baseline pZC had no effect on the response of RBP to zinc supplementation.

Anemia prevalence was reduced by 20% in the IC, but most children were still anemic at 18 months, and anemia remained a severe public health problem in this population. Because SQ-LNS provided the recommended daily allowance of more than 20 micronutrients [15], including iron, vitamin A and vitamin B12, other factors, such as malaria, intestinal helminthes, other infections and hemoglobinopathies may have contributed to the high anemia burden [46]. However, in a separate analysis including only children from the IC, the frequency of malaria episodes during the 9 months of the intervention was not associated with the change in Hb concentration or anemia prevalence at 18 months [47].

At 18 months, the intervention reduced the prevalence of ID by 39–45% compared with the NIC, depending on the ID indicator. Almost all children had high ZPP at 18 months, which suggests that ZPP may not be a useful indicator of iron status in this population due to the high burden of malaria and other infections. Previous studies indicate that ZPP values may be falsely increased in individuals with infections, chronic inflammation, hemoglobinopathies and high lead intakes [48–52].

Our findings regarding the effects of SQ-LNS on Hb and iron status are similar to results from LNS interventions in
other low-income countries. In a study in Ghana, 6 months old infants supplemented for 6 months with SQ-LNS containing 9 mg iron/daily dose also had increased iron status and lower anemia prevalence compared to a non-intervention group [19]. In a randomized clinical trial in Malawi, moderately malnourished children 6–18 months of age who received 25 g/d of a milk-based fortified spread for 12 weeks had a greater change in Hb (mean ± SD: 11 ± 21 g/L) compared to children who did not receive any supplement (1 ± 20 g/L) [53]. In contrast, supplementation of 6–18 months old children with MQ-LNS (46 to 70 g, containing 400 μg vitamin A, 9 mg iron and 9 mg zinc per 46 g) did not affect iron status, Hb concentration or prevalence of anemia during an efficacy trial in rural Honduras compared to a control population who received, similarly to the intervention population, food vouchers and nutrition counselling [20]. Our findings are also similar to results of trials of micronutrient powders (MNP), which provide 12 mg iron, 300 μg retinol and 5 mg zinc per daily dose. A recent meta-analysis found that daily MNP supplementation among 6–23 months old children reduced anemia prevalence by 31% and iron deficiency by 51% compared to placebo or no intervention [54, 55].

The intervention package increased mean plasma RBP concentration, but did not affect the prevalence of low RBP concentration. Similarly, supplementing 6–18 months old Honduran children with MQ-LNS containing 400 μg vitamin A significantly increased plasma retinol concentration after 6 months compared to a control group, although this difference was no longer present after 12 months of supplementation [20].

Our study has several strengths including: 1) the different micronutrient status indicators examined; 2) the large sample size; 3) the continuous training and supervision of field workers responsible for collecting data and obtaining the biological samples; and 4) the post-hoc calculated design effect (1.0–1.7) was accounted for by the inflated sample size in the NIC, which shows that our effective sample size has not been reduced greatly for most of the indicators. We also recognize several limitations of our study, which include the lack of an illness treatment only cohort to differentiate between the effect of SQ-LNS supplementation and the effect of malaria and diarrhea treatment. In addition, due to the lack of information on malaria infection at 18 months, we could not adjust pF and RBP for the presence of asymptomatic malaria, as recently proposed by Wessells et al. [56].

Conclusions

Our results indicate that supplemental zinc provided in SQ-LNS or as a dispersible tablet increased Hb and vitamin A status. Although children who received SQ-LNS containing 10 mg zinc had a lower pF response than those who received SQ-LNS containing less zinc, there were no group-wise differences in the final prevalence of ID or anemia in the IC. The lack of a change in pZC after supplementation with a zinc tablet containing 5 mg zinc and with SQ-LNS containing 5 or 10 mg zinc suggests possible low adherence to the dispersible tablet and/or poor absorption of supplemental zinc when provided with food, or different post-absorptive metabolism of zinc when absorbed. Despite the lack of an effect of zinc supplementation in this study population, SQ-LNS along with malaria and diarrhea treatment was beneficial in reducing the prevalence of ID and anemia and increasing vitamin A status in young children.

Abbreviations

AGP: α-1-acid glycoprotein; BIS: Body iron stores; CRP: C-reactive protein; IC: Intervention cohort; ID: Iron deficiency; IDA: Iron deficiency anemia; NIC: Non-intervention cohort; pF: Plasma ferritin; pZC: Plasma zinc concentration; RBP: Retinol-binding protein; ROH: Retinol; SQ-LNS: Small-quantity lipid-based nutrient supplement; sTR: Soluble transferrin receptor; ZPP: Zinc protoporphyrin

Acknowledgements

We thank the entire iLINS-ZINC study staff and especially the biochemistry team. Special thanks go to Lucien Bado and Faustin Ye (Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso) for planning and coordinating blood sample collection, Antonio Perfecto (Children’s Hospital of Oakland Research Institute, USA) for plasma zinc analyses, Janet Peerson (University of California Davis, USA) for assistance with the programming and statistical analyses, Rosemonde Guissou and Zinewende Ouédraogo for contributing in the coordination of the fieldwork, and the iLINS Project Steering Committee (http://ilins.org) for technical support. Finally, we sincerely appreciate the support of the participating children and their parents, the local communities and the staff of the Health District of Dandé.

Funding

The article is based on research funded in part by a grant to the University of California, Davis from the Bill & Melinda Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

Data used in this analysis are made available to all interested researchers upon request directed to the Project Manager, Mrs. Mary Arimond (marimond@ucdavis.edu).

Authors’ contributions

KHB and SYH were responsible for the design of the study. SA, EYJ and JWS conducted the research and SYH, KHB and JBO supervised data collection. SA completed the statistical analyses and drafted the manuscript. KHB, SYH and EYJ contributed to the writing of the manuscript. All authors read and approved the final manuscript.

Competing interests

KHB has worked as a consultant and later as employee for the Bill & Melinda Gates Foundation. The authors declare that they have no competing interests to declare.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Before enrolling the child in the study, participants primary caregivers’ written consent was obtained. Ethical approval was provided by the...
Institutional Review Board of Centre Muraz (Bobo-Dioulasso, Burkina Faso) and the University of California, Davis (Davis, CA, USA).

Author details
1 Department of Nutrition, Program in International and Community Nutrition, University of California, One Shields Avenue, Davis, CA 95616, USA. 2 Center for Education Policy Research, University of New Mexico, Albuquerque, NM, USA. 3 Pacific Institute for Research and Evaluation, Albuquerque, NM, USA. *Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso. Nutrition and Global Development, Bill & Melinda Gates Foundation, Seattle, WA, USA.

Received: 8 July 2015 Accepted: 21 December 2016

Published online: 02 February 2017

References
1. Black RE. Micronutrient deficiency: an underlying cause of morbidity and mortality. Bull World Health Organ. 2003;81:79.
2. Black RE. Global distribution and disease burden related to micronutrient deficiencies. Nestle Nutr Inst Workshop Ser. 2014;78:21–8.
3. Mayo-Wilson E, Imdad A, Herzer K, Yakoob MY, Bhutta ZA. Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis. BMJ. 2011;343:d5094.
4. Brown KH, Rivera JA, Bhutta Z, Gibson RS, King JC, Lomerdal B, Ruel MT, Sandstrom B, Wasantwisut E, Hotz C. International Zinc Nutrition Consultative Group (IZINCIG) technical document #1. Assessment of the risk of zinc deficiency in populations and options for its control. Food Nutr Bull. 2004;25(1):S99–S203.
5. Bhutta ZA, Das JK, Rizvi A, Gaffey MF, Walker N, Horton S, Webb P, Lartey A, Black RE. Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost? Lancet. 2013;380(9890):452–77.
6. Wessells K, Brown K. Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. PLoS One. 2012;7(11):e50568.
7. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, Ezzati M, Grantham-McGregor S, Katz J, Martorell R, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet. 2013;380(9890):427–51.
8. World Health Organization. Global prevalence of vitamin A deficiency in populations at risk 1995–2005: WHO Global Database on Vitamin A Deficiency. Geneva: WHO; 2009.
9. Imdad A, Herzer K, Mayo-Wilson E, Yakoob MY, Bhutta ZA. Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age. Cochrane Database Syst Rev. 2010;(12):CD008534.
10. Brown KH, Peernum JM, Baker SK, Hess SY. Preventive zinc supplementation among infants, preschoolers, and older prepubertal children. Food Nutr Bull. 2009;30(1):512–40.
11. Fischer Walker C, Kordas K, Stoltzfus RJ, Black RE. Interactive effects of iron and zinc on biochemical and functional outcomes in supplementation trials. Am J Clin Nutr. 2005;82(1):15–22.
12. Christian P, West Jr KP. Interactions between zinc and vitamin A on the biochemical indexes of vitamin A nutrition in children. Am J Clin Nutr. 2002;75(1):92–8.
13. Arimond M, Zeilani M, Jungohann S, Brown KH, Ashorn P, Allen LH, Dewey KG. Considerations in developing lipid-based nutrient supplements for prevention of undernutrition: experience from the International Lipid-Based Nutrient Supplements (iLiNS) Project. Matern Child Nutr. 2013;9(Suppl 1):12094.
14. Iamottu LL, Dulience SJ, Green J, Joseph S, Francisco J, Antenor ML, Lesorogol C, Mounce J, Nickerson NM. Linear growth increased in young children in an urban slum of Haiti: a randomized controlled trial of a lipid-based nutrient supplement. Am J Clin Nutr. 2002;75(1):92–8.
15. Lamort B, Muzila B, Diouf M, Ouédraogo A, Grupi B, Zayas F, Del Mottt L, Dulience SJ, Green J, Joseph S, Francisco J, Antenor ML, Lesorogol C, Mounce J, Nickerson NM. Linear growth increased in young children in an urban slum of Haiti: a randomized controlled trial of a lipid-based nutrient supplement. Am J Clin Nutr. 2014;99(1):198–208.
16. Adou-Afawouah S, Larney A, Brown KH, Zlotkin S, Briend A, Dewey KG. Randomized comparison of 3 types of micronutrient supplements for home fortification of complementary foods in Ghana: effects on growth and motor development. Am J Clin Nutr. 2007;86(2):412–20.
17. Lin CA, Manary MI, Maleta K, Briend A, Ashorn P. An energy-dense complementary food is associated with a modest increase in weight gain when compared with a fortified porridge in Malawian children aged 6–18 months. J Nutr. 2008;138(8):1593–4.
18. Adou-Afawouah S, Larney A, Brown KH, Zlotkin S, Briend A, Dewey KG. Home fortification of complementary foods with micronutrient supplements is well accepted and has positive effects on infant iron status in Ghana. Am J Clin Nutr. 2008;87(4):392–38.
19. Siega-Riz AM, Estrada Del Campo Y, Kinlaw A, Reihart GA, Allen LH, Shahab-Feardows S, Heck J, Suchindran CM, Bentley ME. Effect of supplementation with a lipid-based nutrient supplement on the micronutrient status of children aged 6–18 months living in the rural region of Intibuba, Honduras. Paediatr Perinat Epidemiol. 2014;18(10):12117.
20. World Health Organization. Physical status: The use and interpretation of anthropometry: In: Technical Report Series No. 854. Geneva: World Health Organization; 1995.
21. Hess SY, Abbadebou S, Jimenez EY, Somé JW, Vosti SA, Ouedraogo JP, Guissou RM, Ouedraogo JB, Brown KH. Small-quantity lipid-based nutrient supplements, regardless of their zinc content, increase growth and reduce the prevalence of stunting and wasting in young Burkinabe children: a cluster-randomized trial. PLoS One. 2015;10(3):e0122242.
22. Somé JW, Abbadebou S, Yakes Jimenez E, Hess SY, Ouedraogo JP, Guissou RM, Vosti SA, Ouedraogo JB, Brown KH. Effect of zinc added to a daily small-quantity lipid-based nutrient supplement on diarrhea, fever, and respiratory infections in young children in rural Burkina Faso: a cluster-randomized trial. BMJ Open. 2015;5(9):e007828.
23. Abbadebou S, Hess SY, Yakes Jimenez E, Somé JW, Vosti SA, Guissou RM, Ouedraogo JB, Brown KH. Comparison of methods to assess adherence to small-quantity lipid-based nutrient supplements (SQ-LNS) and dispensible tablets among young Burkinabe children participating in a community-based intervention trial. Matern Child Nutr. 2015;11(4):590–5104.
24. Brown KH, Peernum JM, Rivera J, Allen LH. Effect of supplemental zinc on the growth and serum zinc concentrations of prepubertal children: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2002;75(6):612–71.
25. Hess SY, Yakes EJ, Abbadebou S, Peernum JM, Somé JW, Ouedraogo Z, Ouedraogo JB, Brown KH. Zinc. Comparison of zinc protoporphyrin concentration in capillary whole blood and venous washed red blood cells among young Burkinabe children. FASEB J. 2013;27:1074.
26. Killiflea DW, Armes BN. Magnesium deficiency accelerates cellular senescence in cultured human fibroblasts. Proc Natl Acad Sci. 2008;105(15):5768–73.
27. Wessells KR, Ouedraogo ZP, Rouamba N, Hess SY, Ouedraogo JB, Brown KH. Short-term zinc supplementation with dispersible tablets or zinc sulfate solution yields similar positive effects on plasma zinc concentration of young children in Burkina Faso: a randomized controlled trial. J Pediatr. 2012;160(1):229–35.
28. Erhardt JG, Estes JE, Pfeiffer CM, Besalski HK, Craft NE. Combined measurement of ferritin, soluble transferrin receptor, retinol binding protein, and C-reactive protein by an inexpensive, sensitive, and simple sandwich enzyme-linked immunosorbent assay technique. J Nutr. 2004;134(11):3127–32.
29. Bieri JG, Tolliver TJ, Catignani GL. Considerations in developing lipid-based nutrient supplements for home fortification of complementary foods in Ghana: effects on growth and motor development. Am J Clin Nutr. 1997;32(10):2143–9.
30. Labbe RF, Dewanjii A, McLaughlin K. Observations on the zinc protoporphyrin/heme ratio in whole blood. Clin Chem. 1999;45(1):146–8.
31. Engle-Stone R, Haskell MJ, Ndjeuyiay BO, Nankap M, Erhardt JG, Gimou MM, Brown KH. Plasma retinol-binding protein predicts plasma retinol concentration in both infected and uninfected Cameroon women and children. J Nutr. 2011;141(12):2331–41.
32. Thornham DL, McCabe LD, Haldar S, Wieringa FT, Northrop-Clewes CA, McCabe GP. Adjusting plasma ferritin concentrations to remove the effects of subclinical inflammation in the assessment of iron deficiency: a meta-analysis. Am J Clin Nutr. 2010;92(2):546–55.
33. Cook JD, Flowers CH, Silbase BS. The quantitative assessment of body iron. Blood. 2003;101(9):3559–64.
34. United Nations Children’s Fund, United Nations International Children’s Emergency Fund, United Nations World Health Organisation. Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers. Edited by World Health Organisation, WHO/NHD/01.3. Geneva, Switzerland: 2001: 114. Available at: http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/WHO_NHD_01.3/en/index.html.
36. World Health Organisation. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations. Vitamin and Mineral Nutrition Information System. Geneva: World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.2). Available at: http://www.who.int/nm/vmnis/indicators/serum_ferritin.pdf.

37. Hartika J, Lasseene J, Schwarzbeck A, Strauch M, Hehmann R. Washing erythrocytes to remove interferences in measurements of zinc protoporphyrin by front-face hematofluorometry. Clin Chem. 1992;38(11):2184–9.

38. World Health Organisation Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization; 2006: 312.

39. World Health Organisation. Indicators for assessing infant and young child feeding practices. Conclusions of a consensus meeting held 6–8 November 2007 in Washington D.C., USA. In: Part I: Definition. Geneva, Switzerland; 2008.

40. de Benoist B, Darrton-Hill I, Davidsson L, Fontaine O, Hotz C. Conclusions of the Joint WHO/UNICEF/IAEA/ZINC Interagency Meeting on Zinc Status Indicators. Food Nutr Bull. 2007;28(3):540–54.

41. Brown KH, Lopez de Romana D, Arsenault JE, Peerson JM, Penny ME. Comparison of the effects of zinc delivered in a fortified food or a liquid supplement on the growth, morbidity, and plasma zinc concentrations of young Peruvian children. Am J Clin Nutr. 2007;85(2):538–47.

42. Zlotkin S, Arthur P, Schauer C, Antwi KY, Yeung G, Piekarz A. Home-fortification with iron and zinc and a fortified food or a frozen food, separately and in combination, among Malawian infants: a randomized trial. J Pediatr. 2008;152(5):584–92.

43. Troesch B, van Stuijvenberg ME, Smuts CM, Kruger HS, Bleibinger R, Hurrell RF, Baumgartner J, Zimmermann MB. A micronutrient powder with low doses of highly absorbable iron and zinc reduces iron and zinc deficiency and improves weight-for-age Z-scores in South African children. J Nutr. 2011;141(2):237–42.

44. Dekker LH, Villamor E. Zinc supplementation in children is not associated with decreases in hemoglobin concentrations. J Nutr. 2010;140(5):1035–40.

45. Smith Jr JC. The vitamin A-zinc connection: a review. Ann N Y Acad Sci. 1980;355:62–75.

46. Lutter CK. Iron deficiency in young children in low-income countries and new approaches for its prevention. J Nutr. 2008;138(12):2523–28.

47. Somé J, Abbeddou S, Yakes Jimenez E, Hess S, Ouédraogo Z, Guissou R, Bukh J. Asymptomatic malaria infection affects the interpretation of biomarkers of iron and vitamin A status, even after adjusting for systemic inflammation, but does not affect plasma zinc concentrations among young children in Burkina Faso. J Nutr. 2014;144(12):2050–58.

Submit your next manuscript to BioMed Central
and we will help you at every step:

• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research